|
Getting your Trinity Audio player ready...
|
IGC Pharma, Inc. (NYSE: IGC), a clinical-stage AI biotechnology company focused on Alzheimer’s disease, is gaining investor attention after CEO Ram Mukunda appeared on Bltoomberg TV discussing the company’s lead drug candidate, IGC-AD1, a potential fast-acting therapy for agitation associated with Alzheimer’s dementia.
The company recently reported that enrollment in its Phase 2 CALMA clinical trial has reached approximately 80% of its target, marking a significant milestone as IGC advances one of its most closely watched Alzheimer’s therapeutics programs. The company has also expanded its clinical site network and strengthened its intellectual property portfolio, including new patents tied to its proprietary AI-powered drug discovery platform and IGC-AD1. Listen To Full Interview Now!
Alongside IGC Pharma (NYSE: IGC), investors are watching Volato Group, Inc. (NYSE: SOAR), Abits Group Inc. (Nasdaq: ABTS), HUB Cyber Security Ltd. (Nasdaq: HUBC), Hitek Global Inc. (Nasdaq: HKIT), and Kartoon Studios (NYSE: TOON) as these smallcap stocks under $1, high-volume momentum stocks remain active in early trading.
Beyond Alzheimer’s agitation, IGC Pharma is developing additional programs targeting amyloid plaques, neurodegenerative disease, cognitive decline, precision medicine, and neuroscience innovation, positioning the company at the intersection of artificial intelligence and biotechnology.